Continuing Education Board and Medical Sciences Division

Approved by correspondence 10 August 2021

Title of programme
Master of Science by Coursework in Experimental and Translational Therapeutics

Brief note about nature of change: Removal of detail of what is included in the word count for the dissertation from the regulations

Location of change in Examination Regulations
https://examregs.admin.ox.ac.uk/Regulation?code=mosbciexpeandtranther&srchYear=2021&srchTerm=1&year=2021&term=1

Effective date
For students starting from MT 2021
And
For first examination from MT 2021

Detail of change
text to be deleted struck through
MASTER OF SCIENCE IN EXPERIMENTAL AND TRANSLATIONAL THERAPEUTICS
1. The Medical Sciences Board, in consultation with the Continuing Education Board, shall elect for the supervision of the course a Standing Committee that shall have the power to arrange lectures and other instruction.

2. The course is available on a part time basis only and shall consist of instruction in the theory and practice of Experimental and Translational Therapeutics.

3. The policy of the Continuing Education Board on variable intensity part-time postgraduate study shall apply to this award.

4. The minimum period of registration for the M.Sc. course shall be three terms and the maximum period of registration shall be twelve terms.

5. Every candidate will be required to satisfy the examiners in the following:
   a) six written assignments, each of not more than 4,000 words in length, one from each of the six modules specified;
   b) a dissertation of not more than 15,000 words (including tables, appendices, footnotes but excluding reference list) on a subject selected by the candidate in consultation with the supervisor and approved by the Standing Committee. Approval must be sought no later than the first day of the ninth term of registration. The dissertation must be submitted within three terms of the date of approval, notwithstanding the maximum permitted period of registration.

The assignments and dissertation set out above shall be submitted via the University approved online assessment platform, format to be prescribed in the course handbook, for consideration by such date as the examiners shall determine and shall notify candidates.

6. Candidates may be required to attend a viva voce examination at the end of the course of studies at the discretion of the examiners.

7. The examiners may award a distinction to candidates for the M.Sc.

8. Candidates who fail to satisfy the examiners in any of the assignments or the dissertation under 5 above may be permitted to resubmit work in respect of the part or parts they have failed on not more than one occasion for each assignment without being required to repeat attendance at the relevant module or modules. The resubmission shall normally be within one year of the original failure.

9. Provided the Standing Committee is satisfied that a student on the award has undertaken equivalent study, of an appropriate standard, normally at another institution of higher education, or has appropriate work experience to an equivalent standard, the committee may permit the candidate to be exempted from the submission of a written assignment in respect of up to three modules. In exercising this discretion the Standing Committee shall take into consideration the length of time that has elapsed since the study or work experience was undertaken.

10. The Standing Committee may deem satisfactory completion of a module (including the associated assessment) undertaken prior to registration for the award as having met the examination requirements in respect of that module. Such discretion will normally only be exercised if the time elapsed between commencement of the accredited module concerned and registration for the award is not more than two years. The maximum number of modules taken prior to registration for the award that may be counted in this way shall be three.
Module Schedule

1) Structure of clinical trials and experimental therapeutics
2) Drug development, pharmacokinetics and imaging
3) Pharmacodynamics, biomarkers and personalised therapy
4) Adverse drug reactions, drug interactions, and pharmacovigilance
5) How to do research on therapeutic interventions: protocol preparation
6) Biological therapeutics
7) Any other module as defined by the programme director and approved by the Standing Committee.

* Also available to students on the PG Certificate and Diploma in Health Research

Explanatory Notes